sp-420
Small moleculeexperimental
Clinical trial activity
4 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2014 (NCT02274233)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
COCCOCCOc1ccc(C2=N[C@@](C)(C(=O)O)CS2)c(O)c1- Mol. weight
- 355.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1092665 ↗
Also known as
- sp-420
- sp-420
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05693909 | Phase 2 | Sep 4, 2023 | ICON, Pharmacosmos |
| NCT04741542 | Phase 1 | Mar 9, 2021 | Abfero Pharmaceuticals, Inc, University of Texas, San Antonio |
| NCT03801889 | Phase 2 | May 31, 2019 | Abfero Pharmaceuticals, Inc, American University of Beirut |
| NCT02274233 | Phase 1 | Oct 1, 2014 | Sideris Pharmaceuticals |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abfero Pharmaceuticals, Inc | For profit | 2 | 1 | 2 | 2019 |
| American University of Beirut | Academic/Hospital | 1 | 0 | 1 | 2019 |
| ICON | For profit | 1 | 0 | 1 | 2023 |
| Pharmacosmos | For profit | 1 | 1 | 1 | 2023 |
| Sideris Pharmaceuticals | For profit | 1 | 1 | 1 | 2014 |
| University of Texas, San Antonio | Academic/Hospital | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1